Physician Global Assessment of Lupus Activity (PGA)
Physician Global Assessment of Lupus Activity · Also known as: Physician Global Assessment, PGA-Lupus, Clinician Global Assessment-SLE
The Physician Global Assessment (PGA) is a clinician-rated, single-item measure of overall systemic lupus erythematosus (SLE) disease activity on a visual analogue scale (0–10). Used alongside structured indices like SLEDAI, PGA captures the clinician's integrated judgment of SLE severity, synthesising clinical examination, serology, imaging, and organ-specific findings into a holistic activity score. PGA is simple, practical, and widely used in SLE research and clinical practice as a complementary measure that reflects experienced clinician assessment of disease state.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
PGA is used in SLE research and practice as a complementary outcome alongside structured measures like SLEDAI. Use at baseline and each visit to capture clinician judgment of overall activity. PGA is particularly useful for: (1) clinical trial outcomes, often reported alongside SLEDAI as primary or secondary endpoint; (2) pragmatic settings where formal SLEDAI assessment is time-consuming or incomplete; (3) synthesis of multiorgan disease where clinician judgment guides therapy decisions (e.g., decision to escalate immunosuppression based on integrated PGA assessment); (4) detecting clinically meaningful activity that formal indices may miss or delay in capturing; (5) patient communication—PGA scores provide simple feedback on overall disease status relative to baseline. PGA is validated for adult SLE; not validated for other lupus-like diseases or non-SLE populations.
Strengths & limitations
- Simple, rapid assessment; single question takes <1 minute; practical for busy clinics and pragmatic trials.
- Clinician judgment integration; captures pattern recognition, contextual integration, and clinical experience beyond formal scoring algorithms.
- Responsive to change; sensitive to therapy effects and disease flares; changes correlate with patient outcomes.
- Complements formal indices; PGA and SLEDAI provide synergistic information; discordance prompts investigation (e.g., why is PGA high if SLEDAI is low?).
- Practical for shared decision-making; simple 0–10 scale is easily communicated to patients and enables discussion of activity trends.
- Low cost and minimal burden; no calculations, labs, or equipment required.
- Associated with SLEDAI, serology, and functional outcomes; moderate correlation validates PGA as clinically meaningful.
- Subjective; inter-rater reliability is modest (intraclass correlation ≈ 0.60–0.75); two clinicians assessing the same patient may assign different PGA scores.
- Clinician-dependent; experience, personality, and assessment bias influence PGA; less experienced clinicians may over- or under-estimate activity.
- No formal weighting or algorithm; clinicians may emphasise different features (e.g., one emphasises labs, another organ-specific symptoms), leading to inconsistency.
- Does not specify organ systems; a PGA = 6 could reflect mild multiorgan disease or severe single-organ involvement; specificity is lost.
- Influenced by non-inflammatory factors; fatigue, comorbidities, or medication side effects may elevate PGA independent of SLE activity.
- Less sensitive to subtle changes than detailed indices like SLEDAI; PGA may plateau at high values, losing discrimination.
- Requires trained clinician; PGA is not suitable for patient self-report or primary care without rheumatology training.
Frequently asked
What does a PGA of 6 mean?
A PGA of 6 (on 0–10 scale) indicates moderate-to-high disease activity. Most clinicians would interpret this as clinically apparent SLE with need for therapy adjustment or close monitoring. This patient warrants investigation for organ-specific involvement and assessment of therapy adequacy.
How does PGA differ from SLEDAI?
SLEDAI is a structured index with 24 weighted features and a formula; PGA is a clinician's holistic judgment on a 0–10 scale. SLEDAI is reproducible and standardised; PGA is subjective. Both correlate (r ≈ 0.60–0.70) but capture different information. Use both: SLEDAI for research, PGA for clinical judgment synthesis.
If my PGA is high but my SLEDAI and labs are normal, what does this mean?
Discordance between high PGA and low SLEDAI/normal labs suggests: (1) recent organ involvement not yet captured by labs (early lupus nephritis, early CNS disease); (2) clinician concern based on symptom pattern or examination findings SLEDAI doesn't weight heavily; (3) clinician subjective bias. Investigation with targeted imaging or lab work (24-hour urine, brain MRI) may clarify.
Can PGA be used to diagnose SLE?
No. PGA measures disease activity in diagnosed SLE patients. Diagnosis requires ACR/EULAR SLE classification criteria. PGA is a monitoring tool.
How often should PGA be assessed?
PGA should be assessed at each clinical visit, typically every 3–6 months during treatment titration and every 6–12 months during stable remission. More frequent assessment (monthly) is possible if disease is volatile or if close monitoring is warranted.
Is there an MCID for PGA?
Formal MCID studies for PGA are limited. As a practical guideline, a change of ≥1–2 points on the 0–10 scale likely represents clinically meaningful change, though this depends on baseline. Compare PGA trends over time rather than single-point values.
What if two clinicians rate the same patient with PGA 4 vs. PGA 7?
Discordance reflects the subjective nature of PGA. To improve consistency: (1) establish shared definitions (what does PGA 5 mean?); (2) conduct team reviews where clinicians justify their PGA scores; (3) provide training on PGA anchors; (4) rely on both clinician scores (average if possible) and supplement with SLEDAI for objectivity.
Does PGA reflect damage or activity?
PGA reflects current disease activity (inflammation), not cumulative damage. Damage is measured separately by SLICC/ACR Damage Index. A patient with high PGA from a recent flare has different prognosis than a patient with low PGA but high damage from previous disease.
Sources
- Petri M. Thermodynamic instability in the pathogenesis of lupus nephritis. Nat Rev Rheum. 2016;12(11):635-642. link ↗
- Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis & Rheumatism. 1992;35(6):630-640. DOI: 10.1002/art.1780350606 ↗
How to cite this page
ScholarGate. (2026, June 3). Physician Global Assessment of Lupus Activity. ScholarGate. https://scholargate.app/en/rheumatology/global-assessment-lupus
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Bath Ankylosing Spondylitis Disease Activity IndexRheumatology↔ compare
- Disease Activity Score 28Rheumatology↔ compare
- Systemic Lupus Erythematosus Disease Activity IndexRheumatology↔ compare